23andMe has been granted a patent for binding proteins that target human IL-36 cytokines, blocking their signaling pathways. The patent includes specific sequences for anti-IL-36 antibodies. GlobalData’s report on 23andMe gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights 23andMe Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on 23andMe, was a key innovation area identified from patents.

Anti-il-36 antibody for blocking il-36 signaling pathways

Source: United States Patent and Trademark Office (USPTO). Credit: 23andMe Inc

A recently granted patent (Publication Number: US11884719B2) discloses an anti-IL-36 antibody with specific amino acid sequences in its light chain variable domain (VL) and heavy chain variable domain (VH). The antibody is designed to bind to hu-IL-36a, hu-IL-36-ß, and/or hu-IL-36-? with high binding affinity, inhibiting intracellular signals stimulated by these interleukins. The antibody also demonstrates the ability to decrease the release of IL-8 from primary human keratinocytes when stimulated by IL-36a, IL-36ß, and/or IL-36?. Furthermore, the patent includes claims for multispecific antibodies with distinct binding specificities for different IL-36 interleukins, as well as compositions comprising the disclosed antibodies and a pharmaceutically acceptable carrier.

The patent also covers antibodies that exhibit cross-reactivity with IL-36 interleukins in cynomolgus monkeys, highlighting their potential for broader applications. These antibodies are characterized by their binding affinity to cynomolgus monkey IL-36a, IL-36ß, and IL-36?, measured by equilibrium dissociation constant (KD). Additionally, the antibodies described in the patent are designed to decrease intracellular signals stimulated by IL-36a, IL-36ß, or IL-36? by at least 90%, showcasing their potential therapeutic efficacy. The patent further emphasizes the antibodies' ability to inhibit the release of IL-8 from primary human keratinocytes in response to IL-36 interleukins, underscoring their potential as novel therapeutic agents for inflammatory conditions involving IL-36 signaling pathways.

To know more about GlobalData’s detailed insights on 23andMe, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.